Inclusion Criteria:  The participant and/or their parent/Legally Authorized Representative is willing and able to provide signed informed consent or assent as appropriate Male or female adults 18 to 80 years of age, or adolescents age 12 to 17 years Dependent on parenteral nutrition, defined as receiving PN ≥ 4 days a week for 6 months or longer prior to screening to meet nutritional, caloric, fluid, and/or electrolyte needs The Investigator expects no changes in the lipid, dextrose, amino acid, or vitamin regimen to be medically necessary during the participant's participation in the study Willingness of participant to maintain his/her current habitual oral diet and fluids regimen for the study duration  Exclusion Criteria:  Participants taking steatogenic medications for ≥12 weeks in the past 12 months (e.g., amiodarone, tamoxifen, methotrexate, tetracycline, glucocorticoids, anabolic steroids, over the usual dose of estrogen for hormone replacement therapy, and valproate); those taking any medicine (e.g., metformin, thiazolidinediones, ursodeoxycholic acid, pentoxifylline, S-adenosyl-L-Methionine, and betaine) that could affect the measurement of IFALD within 12 weeks prior to study entry Participants taking potential hepatotoxic medications that in the judgement of the Investigator is causing hepatic abnormalities Participants with a cardiac pacemaker, intravascular stents, other metallic devices, and claustrophobia which are contraindicated to magnetic resonance imaging Participants who took choline supplements or choline-containing multivitamins within 14 days of screening History of major organ transplant (e.g., heart, kidney, liver, etc.)  For more information on eligibility criteria, please contact the sponsor.